Top Markets
Coin of the day
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
株式のランク #33297
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
株価
$0.4264
最終同期: 2022-09-14
時価総額
$7.93M
変化(1日)
-16.44%
変化(1年)
0.00%
US
取引 Caladrius Biosciences, Inc. (CLBS)

カテゴリー

Caladrius Biosciences, Inc.(CLBS)の株式分割履歴
Caladrius Biosciences, Inc.株(シンボル:CLBS)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 17, 2026に行われました。
Aug 17, 2026より前に購入されたCLBS株は、現在0CLBS株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE